Takeda As

Takeda Nycomed As

Nycomed Austria Gmbh

Nycomed Danmark A/s

Nycomed Danmark Aps

Nycomed Pharma As

Takeda Pharma A/s

Poul Bertelsen

Peder Mohr Olsen

Pernille Dybendal Pedersen

Carsten Martini Nielsen

Ingrid Blanka

Henrik Neuschafer Larsen

Henrik Braender

Wolfgang Schoenhofer

Annette Skinh&oslash;j

Jacob Mathiesen

Thomas Thisted

Henrik Neuschaefer Larsen

Henrik Ravn Aage

Magnus Wilhelm Tolleshaug

Hermann Ruckendorfer

Shigeru Itai

Meinolf Vogt

Siegfried Kirchmayr

Annette Skinhøj

Niels Gj&oslash;rl&oslash;v Hansen

Wolfgang Schonhofer

Niels Gjørløv Hansen

The present invention relates inter alia to an apparatus for providing a coiled collagen carrier. An apparatus according to the invention preferably comprises a device for applying moisture to a collagen carrier prior to coiling of the collagen carrier and a coiling device. The coiling device preferably comprises rotatable gripping means for gripping the collagen carrier along an edge and coiling the collagen carrier, and a support device supporting the collagen carrier while being coiled. In another aspect, the invention relates to a production facility wherein an apparatus according to invention is arranged.

Apparatus and process for providing a coiled collagen carrier

The invention relates to a process for the preparation of a rolled compressed collagen carrier and a process for un-rolling said rolled compressed collagen carrier. Said rolled compressed collagen carrier is ready for use in minimally invasive surgery. The invention also relates to a rolled compressed collagen carrier for use in the prevention or treatment of injury associated with performing minimally invasive surgery.

Rolled collagen carrier

The present invention relates to a packaging for storing a form-stable coiled collagen carrier. The form-stable coiled collagen carrier comprises a collagen layer and a coating layer comprising thrombin and fibrinogen and having the shape of an elongated element with a number of windings of the collagen carrier about the longitudinal axis of the elongated element with at least one outer winding(s) being orientated so that the coating layer constitutes the outer surface of each of said outer winding(s). The packaging preferably comprises a container part having a compartment in which at least a part of the coiled collagen carrier is contained.

Packaging for form-stable coiled collagen carrier

The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets.

Particulate comprising a calcium-containing compound and a sugar alcohol

The present invention relates to a method for the preparation of a tablet comprising at least 50% w/w of calcium carbonate, the method comprising

Dissolution stability of calcium carbonate tablets

A pre-compacted materiel comprising one or more calcium-containing compounds and one or more sugar alcohols, wherein the calcium-containing compound having a polycrystallic porous structure. The pre-compacted material is preferably obtained by roller compaction and is suitable for use in the further processing of the pre-compacted material into composition like e.g. tablets.

Pre-compacted calcium-containing compositions

A novel method for the preparation of a tablet comprising a calcium-containing compound, the method involves a melt granulation process by which a sugar alcohol is melted and embeds the calcium-containing compound so that a sufficient taste masking of the chalkiness is substantially achieved and an unpleasant mouth feel of the calcium-containing compound is substantially avoided, while at the same time obtaining a low tablet volume. The method of the invention is especially suitable for the manufacturing of tablets having a high load of a calcium-containing compound.

Melt granulation of a composition containing a calcium-containing compound

The present invention relates to a novel process for the preparation of a granulate comprising a calcium-containing compound as an active substance. The method comprises a method for the preparation of a granulate comprising a calcium-containing compound as an active substance, the method comprising, i) feeding a granulation chamber with a composition comprising the calcium-containing compound, ii) wet-massing the composition with a granulation liquid optionally comprising a pharmaceutically acceptable binder for a time period of at the most 30 sec to obtain a wet granulate, iii) drying the thus obtained wet granulate. A granulate obtained by the present method is especially suitable in the preparation of solid dosage forms, in particular in the preparation of tablets.

Fast wet-massing method for the preparation of calcium-containing compositions

The present invention relates to an oral modified release pharmaceutical composition for the administration of a therapeutically and/or prophylactically effective amount of an active substance (a drug substance) to obtain a relatively fast or quick onset of the therapeutic and/or prophylactic effect. The drug substances contained in a modified release pharmaceutical composition according to the invention are suitably a drug substance which has a very low solubitity under acidic conditions, i.e. under conditions similar to those present in the stomach and/or drug substances which have a pKvalue below about 5.5 such as in a range of from about 4 to about 5. The composition is based on a powder comprising a therapeutically and/or prophylactically active substance and has such a particle size that: when the powder is subjected to a sieve analysis, then at least about 90% w/w of the particles passes through sieves 180 &#x3bc;m and the powder is contacted with an aqueous medium to form a particulate composition, which has such a particle size that when the particulate composition is subjected to a sieve analysis, then at least about 50% w/w of the particles passes through sieve 180 &#x3bc;m. Furthermore, the composition, when tested in accordance with the dissolution method (I) defined herein employing 0.07 N hydrochloric acid as dissolution medium, releases at least about 50% w/w of the active substance within the first 20 min of the test.

Quick release pharmaceutical compositions of drug substances

Novel controlled release pharmaceutical compositions for oral use containing midodrine and/or its active metabolite desglymidodrine. The novel compositions are designed to release midodrine and/or desglymidodrine after oral intake in a manner which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active metabolite desglymidodrine is obtained followed by a prolonged and relatively constant plasma concentration of desglymidodrine. The novel compositions may be designed for administration once or twice daily, i.e. a therapeutically effective concentration of desglymidodrine is maintained for a period of at least 10-16 hours followed by a wash out period of about 8-12 hours in order to avoid the well-known midodrine related side effect with respect to supine hypertension. The therapeutically effective concentration of desglymidodrine is regarded as a plasma concentration of desglymidodrine of at least about 3 ng/ml. A composition is designed to release midodrine and/or desglymidodrine in at least the following consecutive steps: i) an initial relatively fast release of midodrine and/or desglymidodrine (in order to obtain a relatively fast onset of action), ii) a steady release or a slower release than in step 1 of midodrine and/or desglymidodrine (in order to maintain a plasma concentration of desglymidodrine which is prolonged and relatively constant), iii) a second rise in release of midodrine and/or desglymidodrine (in order to take advantage of absorption from the colon, i.e. such a second rise release is designed to take place when the composition (or the disintegrated parts of the composition) reaches the colon; normally this is regarded to take about 8 hours after oral intake, and iv) a decline in release rate corresponding to that essentially all midodrine and/or desglymidodrine have been released from the composition. Also disclosed is a method for treating orthostatic hypotension and/or urinary incontinence, the method comprising administration to a patient in need thereof of an effective amount of midodrine and/or desglymidodrine in a composition according to the invention.

Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine

The invention provides a novel pharmaceutical kit comprising a controlled release pharmaceutical compositions for oral use containing midodrine and/or its active metabolite desglymidodrine. The controlled release composition is designed to release midodrine and/or desglymidodrine after oral intake in a manner which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active metabolite desglymidodrine is obtained, followed by a prolonged and relatively constant plasma concentration of desglymidodrine. The invention also provides a method for treating orthostatic hypotension and/or urinary incontinence, the method comprising administration to a patient in need thereof of an effective amount of midodrine and/or desglymidodrine in a kit.

Growing community of inventors

Roskilde, Denmark

Poul Bertelsen